Champions TumorGrafts Guide the Development of a Novel, Selective Dual BRAF/EGFR Inhibitor, CEP-32496


Case Study Image

Identifying and developing targeted oncology compounds is often an arduous, costly and time-consuming process. As the demand for effective personalized oncology therapies grow, so does the need for a more predictive model solution.

Champions Oncology’s predictive patient-derived xenograft (PDX) models, Champions TumorGrafts, helps bridge the translational gap in oncology drug development by providing a highly-focused and accelerated simulated clinical trial.

The value of Champions TumorGrafts are demonstrated in our latest case study, which shows how the utilization of our PDX models in a screening and efficacy evaluation impacted the development of a novel compound, the dual BRAF-EGR inhibitor, CEP-32496.

To download the case study, please complete the form on the right.

Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology